Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies

Bibliography

• Ghany MG, Strader DB, Thomas DL, Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49(4):1335-74
   PubMed Web of Science ®Google Scholar
• Diago M, Crespo J, Olveira A, Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. Aliment Pharmacol Ther 2007;26(8):1131-8
   PubMed Web of Science ®Google Scholar
• Fried MW, Jensen DM, Rodriguez-Torres M, Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 2008;48(4):1033-43
   PubMed Web of Science ®Google Scholar
• Jensen DM, Marcellin P, Freilich B, Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009;150(8):528-40
   PubMed Web of Science ®Google Scholar
• Roberts SK, Weltman MD, Crawford DH, Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology 2009;50(4):1045-55
   PubMed Web of Science ®Google Scholar
• Brady DE, Torres DM, An JW, Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study. Clin Gastroenterol Hepatol 2010;8(1):66-71
   PubMed Web of Science ®Google Scholar
• Reddy KR, Shiffman ML, Rodriguez-Torres M, Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. Gastroenterology 2010;139(6):1972-83
   PubMed Web of Science ®Google Scholar
• Harrison SA, Abdurakhmanov D, Shiffman ML, Sustained virologic response (SVR) rates are higher among hepatitis C virus (HCV) G1 patients with elevated low-density lipoprotein (LDL) levels when treated with intensified doses of peginterferon alfa-2a (40KD) (Pegasys) plus ribavirin (RBV). Hepatology 2010;52(763A):abstract 921
   Google Scholar
• Singal AG, Waljee AK, Shiffman M, Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther 2010;32(8):969-83
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140(5):346-55
   PubMed Web of Science ®Google Scholar
• Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(5 Suppl 1):S237-44
   PubMed Web of Science ®Google Scholar
• Hamer C. The impact of combination therapy with peginterferon alpha-2a and ribavirin on the energy intake and body weight of adult hepatitis C patients. J Hum Nutr Diet 2008;21(5):486-93
   PubMed Web of Science ®Google Scholar
• Suwantarat N, Tice AD, Khawcharoenporn T, Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to hepatitis C treatment. Int J Med Sci 2010;7(1):36-42
   PubMedGoogle Scholar
• Jensen DM, Freilich B, Andreone P, Easy to assess on-treatement parameters correlate with degree of virological response after 12 weeks of treatment. J Hepatol 2008;48(suppl 2):S297-8
   Google Scholar
• Lindsay KL, Morishima C, Wright EC, Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol 2008;6(2):234-41
   PubMed Web of Science ®Google Scholar
• Giorgini A, Capsoni F, Podda M, Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis. Ann NY Acad Sci 2009;1173:847-57
   PubMed Web of Science ®Google Scholar
• Cooper CL, Al-Bedwawi S, Lee C, Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006;42(12):1674-8
   PubMed Web of Science ®Google Scholar
• Roomer R, Hansen BE, Janssen HL, Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology 2010;52(4):1225-31
   PubMed Web of Science ®Google Scholar
• Horikawa N, Yamazaki T, Izumi N, Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry 2003;25(1):34-8
   PubMed Web of Science ®Google Scholar
• Dieperink E, Ho SB, Tetrick L, Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry 2004;26(3):237-40
   PubMed Web of Science ®Google Scholar
• Kraus MR, Schafer A, Csef H, Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol 2005;11(12):1769-74
   PubMed Web of Science ®Google Scholar
• Kraus MR, Schafer A, Schottker K, Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008;57(4):531-6
   Google Scholar
• Tietz A, Liu J, Peng M, Global review of the rate of interstitial pneumonitis among hepatitis virus-C infected patients treated with pegylated interferon +/- ribavirin. Hepatology 2009;50(Suppl):676A
   Google Scholar
• Ferri C, La CL, Fazzi P, Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection. Br J Rheumatol 1997;36(3):360-5
   PubMedGoogle Scholar
• Okutan O, Kartaloglu Z, Ilvan A, Values of high-resolution computed tomography and pulmonary function tests in managements of patients with chronic hepatitis C virus infection. World J Gastroenterol 2004;10(3):381-4
   PubMed Web of Science ®Google Scholar
• Bourke SJ. Interstitial lung disease: progress and problems. Postgrad Med J 2006;82(970):494-9
   PubMed Web of Science ®Google Scholar
• Reddy KR, Messinger D, Popescu M, Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat 2009;Oct16(10):724-31
   PubMed Web of Science ®Google Scholar
• Hsieh MM, Everhart JE, Byrd-Holt DD, Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med 2007;146(7):486-92
   PubMed Web of Science ®Google Scholar
• Ghany MG, Nelson DR, Strader DB, An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54(4):1433-44
   PubMed Web of Science ®Google Scholar